103
Participants
Start Date
February 29, 2004
Primary Completion Date
March 31, 2007
Study Completion Date
March 31, 2007
Tarceva (Trademark) (erlotinib HCl, OSI-774)
Erlotinib tablets administered orally, 150 mg/day (starting dose) or 100 mg/day (reduced dose), continuous therapy
Combination carboplatin and paclitaxel
Paclitaxel 200 mg/m\^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles
Weill Medical College of Cornell University, New York
Thomas Jefferson University Hospital, Philadelphia
Maryland Hematology/Oncology Associates, Baltimore
Charleston Hematology Oncology, Charleston
University of Miami, Miami
Mount Sinai Cancer Center, Miami Beach
Holy Cross Hospital, Fort Lauderdale
Sarah Cannon Cancer Center, Nashville
East Tennessee Oncology/Hematology, PC, Knoxville
Norton Healthcare, Inc., Louisville
University Hospitals of Cleveland, Cleveland
Gabrail Cancer Center, Canton
FEK Addo, PC, Bismarck
Evanston Northwestern Healthcare, Evanston
Oncology/Hematology Associates of Central Illinois, Peoria
VA Sierra Nevada Health Care System, Reno
Sharp Clinical Oncology Research, San Diego
California Cancer Care, Inc., Greenbrae
Ohio State University, Columbus
Lead Sponsor
OSI Pharmaceuticals
INDUSTRY